{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:43:26Z","timestamp":1786653806706,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The BRCA-associated protein1 (BAP1) immunohistochemical (IHC) stain has emerged as a powerful and inexpensive prognostic tool in uveal melanoma (UM), correlating with UM genetics and outcome. The data on the reliability of BAP1 immunohistochemistry in previously irradiated UM is scant. We aim to assess BAP1 IHC in post-Iodine-125 plaque brachytherapy-treated UM-enucleated eyes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      In a case-control study, the medical records of all patients who underwent enucleation for UM at a major Ocular Oncology Service from December 1\n                      <jats:sup>st<\/jats:sup>\n                      , 2007 to December 31\n                      <jats:sup>st<\/jats:sup>\n                      , 2014 were reviewed. All cases with either chromosome 3 (ch3) status or sufficient follow-up (&gt;5 years or metastasis) were selected. Nuclear BAP1 (nBAP1) immunoreactivity was interpreted as intact (positive in &gt;90% of nuclei), lost (positive in &lt;5% of nuclei), or heterogeneous (positive in 5\u201390% of nuclei). Retina and intratumoral blood vessels served as internal positive controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A comparison of 34 postbrachytherapy UM secondary-enucleated eyes with 47 nonbrachytherapy primary enucleated controls revealed no significant difference with respect to nBAP1 IHC (lost in 41% vs 51%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.19), ch3 status (ch3 monosomy in 59% vs 60%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.48), and outcome (metastatic disease in 44% vs 47%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.8). Association of nBAP1 IHC with ch3 status and outcome [intact nBAP1\/(ch3 disomy and\/or no metastasis) and lost nBAP1 (ch3 monosomy and\/or metastasis)] in post-brachytherapy UM was significantly lower when compared with non-brachytherapy tumors [21\/30 (70%) vs 41\/44 (93%),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004*].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Although nBAP1 IHC stain is a strong prognostic tool in UM, its association with ch3 status, and outcome in postbrachytherapy UM was significantly lower compared with nonbrachytherapy tumors due to pitfalls in the interpretation of nBAP1 immunoreactivity in irradiated UM. This test should be used judiciously in the prognostication of postbrachytherapy-enucleated UM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_648_23","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T04:00:11Z","timestamp":1713585611000},"page":"S459-S467","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["BRCA-associated protein1 (BAP1) immunohistochemical stain reliability in postbrachytherapy uveal melanoma enucleation specimens"],"prefix":"10.4103","volume":"72","author":[{"given":"Maya","family":"Eiger-Moscovich","sequence":"first","affiliation":[{"name":"Department of Pathology, Wills Eye Hospital, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Department of Ophthalmology, Hadassah Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L","family":"Shields","sequence":"additional","affiliation":[{"name":"Ocular Oncology Service, Wills Eye Hospital, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph C","family":"Eagle","sequence":"additional","affiliation":[{"name":"Department of Pathology, Wills Eye Hospital, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Milman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Wills Eye Hospital, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ophtha.2019.04.027","article-title":"Genetic analysis of uveal melanoma in 658 patients using the cancer genome Atlas classification of uveal melanoma as A, B, C, and D","volume":"126","author":"Vichitvejpaisal","year":"2019","journal-title":"Ophthalmology"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000508382","article-title":"Gene expression profiling in uveal melanoma: Five-Year prospective outcomes and meta-analysis","volume":"6","author":"Aaberg","year":"2020","journal-title":"Ocul Oncol Pathol"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative Ocular Oncology Group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/PAS.0000000000000645","article-title":"Comparing the prognostic value of BAP1 mutation pattern, chromosome 3 status, and BAP1 immunohistochemistry in uveal melanoma","volume":"40","author":"van de Nes","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ajo.2018.03.005","article-title":"Correlation of Immunocytochemistry of BRCA1-associated Protein-1 (BAP1) with other prognostic markers in uveal melanoma","volume":"189","author":"Glasgow","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.3390\/cancers13215347","article-title":"Prognostic factor utility of BAP1 immunohistochemistry in uveal melanoma: A single center study in Spain","volume":"13","author":"Tabuenca Del Barrio","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000502550","article-title":"BAP1 immunoreactivity correlates with gene expression class in uveal melanoma","volume":"6","author":"See","year":"2020","journal-title":"Ocul Oncol Pathol"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/gcc.22541","article-title":"Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma","volume":"57","author":"Patrone","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0161-6420(90)32363-1","article-title":"Enucleation after plaque radiotherapy for posterior uveal melanoma. Histopathologic findings","volume":"97","author":"Shields","year":"1990","journal-title":"Ophthalmology"},{"key":"R11-20260504","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.ophtha.2016.05.028","article-title":"Prognostic biopsy of choroidal melanoma after proton beam radiation therapy","volume":"123","author":"Hussain","year":"2016","journal-title":"Ophthalmology"},{"key":"R12-20260504","first-page":"e14","article-title":"Uveal melanoma gene expression status post radiotherapy","volume":"91","author":"Gold","year":"2014","journal-title":"Optom Vis Sci"},{"key":"R13-20260504","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/bjophthalmol-2019-315363","article-title":"Effects of plaque brachytherapy and proton beam radiotherapy on prognostic testing: A comparison of uveal melanoma genotyped by microsatellite analysis","volume":"104","author":"Thornton","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R14-20260504","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1136\/bjophthalmol-2015-307057","article-title":"Concordant chromosome 3 results in paired choroidal melanoma biopsies and subsequent tumour resection specimens","volume":"99","author":"Coupland","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R15-20260504","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00717-013-0195-0","article-title":"Genetic analysis of uveal melanoma by array comparative genomic hybridization before and after radiotherapy","volume":"27","author":"Wackernagel","year":"2013","journal-title":"Spektrum der Augenheilkunde"},{"key":"R16-20260504","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3390\/cancers11081173","article-title":"Comparative cytogenetic abnormalities in paired choroidal melanoma samples obtained before and after proton beam irradiation by transscleral fine-needle aspiration biopsy and endoresection","volume":"11","author":"Matet","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R17-20260504","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1167\/iovs.15-17092","article-title":"Radiation treatment affects chromosome testing in uveal melanoma","volume":"56","author":"Dogrus\u00f6z","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R18-20260504","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0002-9394(01)01362-9","article-title":"Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy","volume":"133","author":"Brantley","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"R19-20260504","first-page":"2081","article-title":"A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques","volume":"38","author":"Schilling","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-20260504","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.3390\/ijms21175993","article-title":"Ionizing radiation-induced epigenetic modifications and their relevance to radiation protection","volume":"21","author":"Belli","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R21-20260504","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ophtha.2017.07.018","article-title":"Uveal melanoma nuclear BRCA1-associated Protein-1 immunoreactivity is an indicator of metastasis","volume":"125","author":"Szalai","year":"2018","journal-title":"Ophthalmology"},{"key":"R23-20260504","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: A distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzyigitoglu","year":"2016","journal-title":"Ophthalmology"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_648_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:42:40Z","timestamp":1786650160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_648_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":22,"journal-issue":{"issue":"Suppl 3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_648_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"assertion":[{"value":"2023-03-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}